Sunitinib First-line Treatment in Metastatic Renal Cell Carcinoma: Costs and Effects.

Background/aim: Tyrosine kinase inhibitors are important in the treatment of metastatic renal cell cancer (mRCC). The aim of the study was to evaluate the costs and effects of sunitinib in mRCC.

Patients And Methods: A total of 81 mRCC patients who received first-line sunitinib therapy between 2010 and 2014 were recruited.